Literature DB >> 16164578

Left ventricular function and calcium phosphate plasma levels in uraemic patients.

F Galetta1, A Cupisti, F Franzoni, F R Femia, M Rossi, G Barsotti, G Santoro.   

Abstract

UNLABELLED: BACKGROUND. Recent investigations have focused on the pathogenetic role of disturbances of calcium phosphate metabolism in causing cardiovascular morbidity and mortality in haemodialysis patients. The aim of the present study was to assess left ventricular function and its relationship to phosphate and calcium plasma levels in stable uraemic patients on haemodialysis treatment.
METHODS: Twenty uraemic patients (mean age 51+/-13 years) on maintenance haemodialysis and free from overt cardiac dysfunction, and 20 healthy volunteers underwent standard echocardiography, tissue Doppler-derived early (E(m)) and late (A(m)) diastolic velocities, tissue characterization with cyclic variations of integrated backscatter (CV-IBS), and serum biochemistry.
RESULTS: With respect to tissue Doppler imaging (TDI), uraemic patients showed a lower E(m) peak, a higher A(m) peak, and a reduced E(m)/A(m) ratio of both interventricular septum and lateral wall (0.01>P<0.001) than controls. CV-IBS of both septum and posterior wall was significantly smaller in uraemic patients than in the control subjects (P<0.001). Moreover, the E(m)/A(m) ratio of septum and lateral wall were negatively related to serum phosphorus and to calcium phosphate product (P<0.001 for all). Accordingly, an inverse relationship was also found between CV-IBS of septum and lateral wall and calcium phosphate product and phosphorus (P<0.05 for all).
CONCLUSIONS: These results showed early cardiac impairment of diastolic myocardial function evaluated by TDI and IBS analysis, and a close relationship between these changes and the calcium-phosphate plasma levels. These findings are well in keeping with the important role of hyperphosphataemia as a risk factor for cardiovascular damage, and justify the effort for optimal control of calcium phosphate metabolism in uraemic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16164578     DOI: 10.1111/j.1365-2796.2005.01544.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  20 in total

Review 1.  Diagnosis and Management of Heart Failure in Long-Term Dialysis Patients.

Authors:  Ashraf S Abdo
Journal:  Curr Heart Fail Rep       Date:  2017-10

2.  Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.

Authors:  Anna Jovanovich; Joachim H Ix; John Gottdiener; Kim McFann; Ronit Katz; Bryan Kestenbaum; Ian H de Boer; Mark Sarnak; Michael G Shlipak; Kenneth J Mukamal; David Siscovick; Michel Chonchol
Journal:  Atherosclerosis       Date:  2013-09-13       Impact factor: 5.162

Review 3.  Volume Balance and Intradialytic Ultrafiltration Rate in the Hemodialysis Patient.

Authors:  Jason A Chou; Kamyar Kalantar-Zadeh
Journal:  Curr Heart Fail Rep       Date:  2017-10

Review 4.  Mineral metabolism and cardiovascular disease in CKD.

Authors:  Hideki Fujii; Nobuhiko Joki
Journal:  Clin Exp Nephrol       Date:  2017-01-06       Impact factor: 2.801

Review 5.  The Ebb and Flow of Echocardiographic Cardiac Function Parameters in Relationship to Hemodialysis Treatment in Patients with ESRD.

Authors:  Charalampos Loutradis; Pantelis A Sarafidis; Christodoulos E Papadopoulos; Aikaterini Papagianni; Carmine Zoccali
Journal:  J Am Soc Nephrol       Date:  2018-03-28       Impact factor: 10.121

Review 6.  Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?

Authors:  Rukshana Shroff; Catherine Quinlan; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2010-11-16       Impact factor: 3.714

Review 7.  Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.

Authors:  Luca Di Lullo; Antonio Gorini; Domenico Russo; Alberto Santoboni; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2015-07-15       Impact factor: 2.041

Review 8.  Phosphate: an old bone molecule but new cardiovascular risk factor.

Authors:  Navid Shobeiri; Michael A Adams; Rachel M Holden
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

Review 9.  Management of natural and added dietary phosphorus burden in kidney disease.

Authors:  Adamasco Cupisti; Kamyar Kalantar-Zadeh
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

10.  Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros; Haridian Herrera; Javier García
Journal:  Clin J Am Soc Nephrol       Date:  2009-09-24       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.